Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease

Trial Identifier: D6800C00005
Sponsor: AstraZeneca
Start Date: March 2025
Primary Completion Date: August 2027
Study Completion Date: August 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Leicester, GB, Le5 4PW
GB Liverpool, GB, L22 0LG
GB London, GB, SE5 8AZ
GB Manchester, GB, M13 9WL
US, AL Alabaster, AL, US, 35007
US, AL Birmingham, AL, US, 35205
US, AL Irondale, AL, US, 35210
US, CA Gardena, CA, US, 90247
US, CA Los Angeles, CA, US, 90095
US, CA Northridge, CA, US, 91324
US, CA Valencia, CA, US, 91355
US, FL Brandon, FL, US, 33511
US, FL Orlando, FL, US, 32808
US, GA Atlanta, GA, US, 30322
US, GA Macon, GA, US, 31217
US, LA Lafayette, LA, US, 70508
US, MD Bethesda, MD, US, 20889
US, MI Roseville, MI, US, 48066
US, MS Tupelo, MS, US, 38801
US, NC Greenville, NC, US, 27834
US, NC Winston Salem, NC, US, 27103
US, NC Winston-Salem, NC, US, 27157
US, OH Cincinnati, OH, US, 45246
US, SC Anderson, SC, US, 29621
US, SC Spartanburg, SC, US, 29306
US, TN Chattanooga, TN, US, 37404
US, TX Dallas, TX, US, 75234
US, TX Dallas, TX, US, 75235
US, TX Mesquite, TX, US, 75149
US, TX Pearland, TX, US, 77584
US, TX San Antonio, TX, US, 78212
US, VA Alexandria, VA, US, 22311